Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,930 shares of Common Stock in an open-market transaction at $62.07 per share. The sale was reported as a direct ownership transaction. After this trade, Callos continues to hold 78,185 shares of Cytokinetics common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing resale notices for Common stock related to multiple 10b5-1 sales attributed to Andrew Callos. The filing lists dated sales and per‑trade quantities with associated cash amounts, including 03/05/2026 sales of 15,000 and 11,000 shares.
Cytokinetics President & CEO Robert I. Blum reported equity awards and updated holdings. On March 15, 2026, he received an annual grant of 75,258 shares of common stock as restricted stock units that convert 1:1 into common shares.
These RSUs vest 40% on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third, subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He was also granted 1,665 incentive stock options and 111,864 non-qualified stock options at an exercise price of $60.06 per share, vesting in 48 equal monthly installments and expiring on March 14, 2036. Following these awards, his direct common stock holdings total 466,931 shares. Indirectly, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics executive Andrew Callos received new equity awards as part of his compensation. On March 15, 2026, he was granted 1,665 incentive stock options and 29,480 non-qualified stock options to buy common stock at an exercise price of $60.06 per share, expiring on March 14, 2036.
These stock options vest in 48 equal monthly installments, subject to his continued employment and the company’s Amended and Restated 2004 Equity Incentive Plan. He also received 20,646 restricted stock units as an annual equity award and 13,320 restricted stock units as a special supplemental award, which convert 1:1 into common shares as they vest over one to three years.
Following these awards, Callos directly holds 81,824 shares of common stock. All transactions are coded as awards or acquisitions, with no open-market purchases or sales reported in this filing.
Cytokinetics Inc. reported that Chief Legal & Admin Officer Jeffrey Hessekiel received new equity awards. On March 15, 2026, he was granted 8,325 incentive stock options and 22,820 non-qualified stock options, each with an exercise price of $60.06 per share and expiring on March 14, 2036. These stock options vest in 48 equal monthly installments, conditioned on his continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He also received an annual equity award of 20,646 shares of common stock in the form of restricted stock units that convert 1-for-1 into common shares and vest 40% on each of the first and second anniversaries of the grant date and 20% on the third anniversary, also subject to continued employment. Following these awards, he directly holds 107,943 shares of Cytokinetics common stock.
Cytokinetics EVP and CFO Sung Lee received new equity awards. On 2026-03-15, Lee was granted 20,646 shares of Common Stock as an annual restricted stock unit award, increasing his direct holdings to 92,062 shares. He also received incentive and non-qualified stock options on 1,665 and 29,480 shares at an exercise price of $60.0600, vesting over four years.
Cytokinetics EVP of Research & Development Fady Ibraham Malik received new equity awards. On March 15, 2026, he was granted 27,306 shares of common stock as restricted stock units, increasing his direct common share holdings to 165,935.
He was also granted incentive stock options on 1,665 shares and non-qualified stock options on 39,527 shares, each with a $60.06 exercise price and expiring on March 14, 2036. The RSUs vest 40% after one year, 40% after two years, and 20% after three years, while the options vest in 48 equal monthly installments, all subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,709 shares of Common Stock in an open-market transaction at $61.03 per share. After this sale, he directly holds 46,149 shares, so the transaction represents a relatively small portion of his total reported holdings.
Andrew Callos reported multiple planned sales of Common Stock under a Rule 10b5-1 plan. The filing lists individual dispositions dated between 12/29/2025 and 03/09/2026, including transactions of 15,000 shares on 01/05/2026 and 15,000 shares on 02/05/2026, with listed proceeds for each trade. The transactions are described as 10b5-1 sales.
CYTOKINETICS INC executive Andrew Callos reported a small, tax-related stock sale. On the vesting of restricted stock units, he sold 2,582 shares of common stock on March 9, 2026 at $60.72 per share to satisfy company tax withholding obligations, and now directly holds 47,858 shares.